Search Results

Your search for Julia Cipriano, MD,Julia Cipriano, MD matches 2 pages

Showing 1 - 2

By JULIA CIPRIANO, MS / September 10, 2025 / 2025 ASCO Annual Meeting

Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...

lung cancer

By Julia Cipriano, MD / November 25, 2024 / 2024 IASLC WCLC

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

Sep

Today In Oncology

Search Results

Your search for Julia Cipriano, MD,Julia Cipriano, MD matches 2 pages

Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease

Can Nicotinamide Lessen the Risk of Skin Cancer Development

Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia

Clonal Hematopoiesis

Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With AML